Abstract | BACKGROUND: DESIGN: Two 16-week, open-label studies conducted in 122 study centres across the United Kingdom and Canada (JEWEL 1) and 113 centres across 11 European countries (JEWEL 2). METHODS: Patients with uncontrolled BP and controlled/uncontrolled LDL-C qualifying for treatment according to local governing guidelines were administered single-pill amlodipine/atorvastatin with appropriate lifestyle modification. Eight dosages of amlodipine/atorvastatin (5/10-10/80 mg) were titrated to achieve country-specific BP and LDL-C targets. The primary outcome was the percentage of patients reaching country-specific BP and LDL-C targets in 16 weeks. RESULTS: Among 2245 patients enrolled in the studies (JEWEL 1, n = 1138; JEWEL 2, n = 1107), 62.9% in JEWEL 1 and 50.6% in JEWEL 2 achieved both country-specific BP and LDL-C goals. BP was reduced by 20.4/10.7 and 21.8/12.6 mmHg in JEWEL 1 and JEWEL 2, respectively, and reductions in LDL-C were 0.90 mmol/l (34.8 mg/dl) and 1.09 mmol/l (42.2 mg/dl), respectively. The most common adverse events were peripheral oedema (11.0%), joint swelling (2.9%) and headache (2.9%), of which, only oedema was linked to study treatment. CONCLUSION: Single-pill amlodipine/atorvastatin is an effective and well-tolerated treatment, which in a real-world setting helped more than half of the patients achieve both BP and LDL-C targets as recommended by local guidelines. Although fewer patients met their goals in JEWEL 2 than JEWEL 1, reductions in BP and LDL-C were slightly greater in JEWEL 2, suggesting that the observed differences are likely because of more stringent targets in Europe than in the UK/Canada.
|
Authors | Frederick D Richard Hobbs, Gianfranco Gensini, Giovanni B John Mancini, Athanasios J Manolis, Beverly Bauer, Jacques Genest, Ross D Feldman, Peter Harvey, Trond G Jenssen, Pedro Marques da Silva, JEWEL Study Group |
Journal | European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
(Eur J Cardiovasc Prev Rehabil)
Vol. 16
Issue 4
Pg. 472-80
(Aug 2009)
ISSN: 1741-8275 [Electronic] England |
PMID | 19407658
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Antihypertensive Agents
- Drug Combinations
- Heptanoic Acids
- Pyrroles
- Tablets
- Amlodipine
- Atorvastatin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amlodipine
(administration & dosage)
- Anticholesteremic Agents
(administration & dosage)
- Antihypertensive Agents
(administration & dosage)
- Atorvastatin
- Blood Pressure
(drug effects)
- Canada
- Cardiovascular Diseases
(prevention & control)
- Drug Combinations
- Dyslipidemias
(drug therapy)
- Europe
- Female
- Heptanoic Acids
(administration & dosage)
- Humans
- Hypertension
(drug therapy)
- Lipid Metabolism
(drug effects)
- Male
- Middle Aged
- Practice Guidelines as Topic
- Pyrroles
(administration & dosage)
- Tablets
- Treatment Outcome
|